Glenmark Life Sciences Limited (GLS)

1,005.1

INR
-31.70(-3.06%)
As of March 12, 2025 5:35:00 AM

About Glenmark Life Sciences Limited

Alivus Life Sciences Ltd. is a pivotal player in the biotechnology and pharmaceutical industries, focusing on the research, development, and commercialization of innovative healthcare solutions. The primary purpose of Alivus is to improve patient health outcomes by advancing therapies that address a wide range of diseases, primarily concentrating on areas such as oncology, immunology, and neurology. Notable for its commitment to pioneering research, Alivus Life Sciences allocates substantial resources towards developing cutting-edge treatments and utilizes state-of-the-art technology in its laboratories and manufacturing facilities. The company plays a significant role in the health sector, providing vital pharmaceutical solutions that contribute to global progress in medical science. As a listed entity, it maintains strong ties with healthcare providers, governmental agencies, and patients, emphasizing its importance in the healthcare supply chain. Through strategic partnerships and rigorous clinical trials, Alivus Life Sciences Ltd. continues to uphold its reputation as a leader in the drive towards innovative medical breakthroughs, enhancing therapeutic options available to various patient populations worldwide.

RevenueLast 12 months
NA
+NA YoY
EBITDALast 12 months
NA
Price to Sales RatioTTM
6.03
Operating MarginLast 12 months
23.53
+-19.7% quarterly YoY
Market Cap
13304.65 CrINR
Employees
2014
CEO
Dr. Yasir Yusufali Rawjee Ph.D.
Website